Anakinra (Kineret®)

DRUG5 trials

Sponsors

Amgen, Kevin McNerney, University Health Network, Toronto, Monash Medical Centre, Swedish Orphan Biovitrum

Conditions

Adult Onset Still's Disease (AOSD)B-Acute Lymphoblastic LeukemiaCAR-T Cell TherapyCytokine Release SyndromeEarly Stage Triple Negative ER Low Breast CancerImmune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like SyndromeImmune Effector Cell Associated Neurotoxicity SyndromeInflammation

Phase 1

Pre-emptive Anakinra for Cytokine Event Reduction

WithdrawnNCT06703216

Kevin McNerneyB-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy, Cytokine Release Syndrome +2

Start: 2026-10-01End: 2030-02-28Updated: 2026-08-13

Phase 2

IL-1 Inhibition in Early TNBC

WithdrawnNCT06710197

University Health Network, TorontoEarly Stage Triple Negative ER Low Breast Cancer

Start: 2025-03-05End: 2026-02-12Updated: 2026-03-05

Anakinra Pilot 2 - A Study to Optimise Dose and Route of Administration of Anakinra in Preterm Infants

RecruitingNCT07254000

Monash Medical CentreInflammation, Premature Infants, Very Premature Infants

Start: 2025-06-27End: 2026-12-31Target: 24Updated: 2025-11-28

Phase 3

Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA)

CompletedNCT00117091

AmgenRheumatoid Arthritis

Updated: 2007-12-24

Phase 4

An Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD)

WithdrawnNCT07706868

Swedish Orphan BiovitrumAdult Onset Still's Disease (AOSD), Systemic Juvenile Idiopathic Arthritis (sJIA)

Start: 2025-09-01End: 2028-09-30Updated: 2026-07-16